Superior Prophylactic Effectiveness of a Recombinant <scp>FVIIIFc</scp> Over Standard Half‐Life <scp>FVIII</scp> in Hemophilia A: A‐<scp>SURE</scp> Study
rFVIIIFc has superior prophylactic effectiveness versus SHL FVIII, providing higher bleed protection with fewer injections and lower factor consumption.
Authors
- Pål André Holme (ORCID: https://orcid.org/0000-0002-3888-2905)
- María Teresa Álvarez Román (ORCID: https://orcid.org/0000-0003-3296-4288)
- Stefan Lethagen (ORCID: https://orcid.org/0000-0002-8436-1780)
- C. R. M. Hay (ORCID: https://orcid.org/0000-0002-0162-6828)
- Flora Peyvandi (ORCID: https://orcid.org/0000-0001-7423-9864)
- Christine Biron‐Andréani (ORCID: https://orcid.org/0000-0002-7549-8718)
- Johannes Oldenburg (ORCID: https://orcid.org/0000-0002-1585-4100)
- Linda Bystrická (ORCID: https://orcid.org/0000-0002-9787-7866)
- Håkan Malmström (ORCID: https://orcid.org/0000-0003-3315-5618)
- Annarita Tagliaferri
Institutions
- University of Parma (IT)
- Oslo University Hospital (NO)
- University of Bonn (DE)
- University of Oslo (NO)
- University of Milan (IT)
- University Hospital Bonn (DE)
- Manchester Royal Infirmary (GB)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Swedish Orphan Biovitrum (Sweden) (SE)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2024-10-21
- DOI
- https://doi.org/10.1111/ejh.14309
- Citations
- 3
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- Sanofi
- International Society on Thrombosis and Haemostasis
- Swedish Orphan Biovitrum